^
    Back
    Association details:
    Biomarker:CD22 expression
    Cancer:B Acute Lymphoblastic Leukemia
    Drug Class:CD19-targeted CAR-T immunotherapy +
    CD22-targeted CAR-T immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL

    Published date:
    05/11/2023
    Excerpt:
    All patients expressed CD22 antigen (>80% leukemic cells displaying CD22) before treatment….For heavily treated r/r B-ALL patients including those after treatment with both CD19 and CD22 CAR-T cells, our two-dose cost-saving regimen of inotuzumab resulted in a CR rate of 66.7%...